A Single-arm, Open Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 in Patients With Advanced Solid Tumors
Latest Information Update: 14 Apr 2025
At a glance
- Drugs FS 8002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Pushi Medical Science
Most Recent Events
- 09 Apr 2025 Status changed from not yet recruiting to recruiting.
- 27 Feb 2025 New trial record